EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and Safety of Hydroxychloroquine for the Treatment of COVID-19: An empirical study

Vivek Saraswat, Pradeepta Sekhar Patro, Sourav Rampal, Madireddy Sirisha, Mukesh Sharma, Monika Monika

Health Leadership and Quality of Life · 06.08.2025 · 4 · 626

DOI: 10.56294/hl2025626 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Leadership and Quality of Life, online erschienen am 06.08.2025. Verfasst von Vivek Saraswat und 5 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The new coronavirus disease epidemic of 2019 (COVID-19) has spread worldwide. A quick solution to meet the urgent demand for effective treatment may be drug repurposing. To treat COVID-19, evaluated the clinical effectiveness of hydroxychloroquine and chloroquine. The individuals that received a modest COVID-19 score were randomized to obtain the control therapy or hydroxychloroquine 800 milligrams once daily on Day 7 and 250 milligrams for nine days, except the evaluated the clinical effectiveness of hydrochloride and chlorin equine. Compared to the control group (CtrlGrp) (Group 3), adverse reactions were observed more frequently in those taking chloroquine (Group 1) and hydroxychloroquine (Group 2). The time to clinical recovery (TTCR) was shortened in the Group 1 relation to the CtrlGrp. In the Group 2, there was a tendency toward lower TTCR. Chloroquine and Group 2 reached viral RNA negative substantially faster than the CtrlGrp. The typical instances to become RNA negative in the groups treated with chloroquine, hydroxychloroquine, and controls comprised two days, two weeks, and seven days, correspondingly. Both the length of hospitalization and the results of the lung computed tomography (CT) indicated improvements in the hydroxychloroquine and chloroquine pharmacologic categories. This research provides evidence that hydrochlorothiazide may be used to treat mild COVID-19, and it complements more excellent investigations.

Zitieren

APA

Saraswat, V., Patro, P. S., Rampal, S., Sirisha, M., Sharma, M., & Monika, M. (2025). Efficacy and Safety of Hydroxychloroquine for the Treatment of COVID-19: An empirical study. Health Leadership and Quality of Life, 4, 626. https://doi.org/10.56294/hl2025626

Vancouver

Saraswat V, Patro PS, Rampal S, Sirisha M, Sharma M, Monika M. Efficacy and Safety of Hydroxychloroquine for the Treatment of COVID-19: An empirical study. Health Leadership and Quality of Life. 2025;4:626. doi:10.56294/hl2025626

BibTeX
@article{Saraswat2025,
  author = {Saraswat, Vivek and Patro, Pradeepta Sekhar and Rampal, Sourav and Sirisha, Madireddy and Sharma, Mukesh and Monika, Monika},
  title = {Efficacy and Safety of Hydroxychloroquine for the Treatment of COVID-19: An empirical study},
  journal = {Health Leadership and Quality of Life},
  year = {2025},
  volume = {4},
  pages = {626},
  doi = {10.56294/hl2025626}
}
Kostenlos starten →